Both in Pharmaceuticals
Roivant Sciences vs Royalty Pharma
Over the past year ROIV returned +141.7% and RPRX returned +65.2%; their daily moves had a correlation of 0.10.
ROIV +141.7% RPRX +65.2%Growth of $1, one year, split-adjusted
| Metric | ROIV | RPRX |
|---|---|---|
| Price | $36.50 | $58.22 |
| Market cap | $26.36B | $25.92B |
| Today | −1.30% | −0.26% |
| 1 month | +5.2% | −4.3% |
| 6 months | +38.2% | +25.6% |
| Year to date | +68.2% | +50.7% |
| 1 year | +140.6% | +66.2% |
| Revenue growth (YoY) | −33.5% | +16.5% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −13164.8% | 2.7% |
| P/E (TTM) | — | 31.8× |
| Price / sales | 3,500.4× | 10.2× |
| Net cash | $3.84B | -$8.23B |
| Dividend yield | — | 1.61% |
| Volatility (60d) | 49.4% | 24.0% |
| Short % of float | 9.8% | 2.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).